Effect of apolipoprotein E4 allele on plasma LDL cholesterol response to diet therapy in type 2 diabetic patients.

OBJECTIVE The aim of this study was to investigate the effect of apolipoprotein (apo)E4 allele on plasma LDL cholesterol response to calorie-restricted diet therapy in type 2 diabetic patients. RESEARCH DESIGN AND METHODS Twenty-four diabetic patients with the apoE3/3 genotype and 11 diabetic patients with the apoE4/3 genotype were recruited. Participants were hospitalized for calorie-restricted diet therapy (25.0 kcal. kg body wt(-1). day(-1)) for 14 days. Body weight, fasting plasma glucose (FPG) levels, and plasma lipid levels on hospital days 1 and 14 were compared between the two apoE genotype groups. RESULTS There were no significant differences in baseline FPG levels, HbA(1c) levels, BMI, and plasma levels of total cholesterol, triglyceride, and HDL cholesterol between the two apoE genotype groups, but baseline plasma levels of LDL cholesterol were significantly higher in the apoE4/3 group than in the apoE3/3 group. Body weight decreased slightly and FPG levels decreased significantly after diet therapy in both apoE genotype groups. In the apoE3/3 group, only plasma levels of triglyceride decreased significantly after diet therapy, whereas in the apoE4/3 group, plasma levels of triglyceride, total cholesterol, and LDL cholesterol decreased significantly after diet therapy. The decrease (percentage of change) in total cholesterol (-16.3 vs. -6.6%) and LDL cholesterol (-15.6 vs. -0.7%) after diet therapy was significantly greater in the apoE4/3 group than in the apoE3/3 group. CONCLUSIONS Calorie-restricted diet therapy is more effective in reducing plasma LDL cholesterol in type 2 diabetic patients with the apoE4 allele.

[1]  I. Makino,et al.  Relationship of Metabolic Control and Body Weight to Hypercholesterolemia in NIDDM Patients With Apolipoprotein E4 , 1991, Diabetes Care.

[2]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[3]  Rinzler Sh.  Primary prevention of coronary heart disease by diet. , 1968, Bulletin of the New York Academy of Medicine.

[4]  J. Pennington.  Food Composition Databases for Bioactive Food Components , 2002 .

[5]  M. Fujishima,et al.  Diabetes and Cardiovascular Disease in a Prospective Population Survey in Japan: The Hisayama Study , 1996, Diabetes.

[6]  P. Wilson,et al.  Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[7]  K. Watanabe,et al.  Apolipoprotein E Polymorphism and Hyperlipemia in Type II Diabetics , 1986, Diabetes.

[8]  Michio Obara,et al.  Food Composition Database. World-Wide-Web-based Food Composition Database System. , 1997 .

[9]  Y. Yazaki,et al.  Apolipoprotein E Polymorphism Is Associated With Plasma Cholesterol Response in a 7-day Hospitalization Study for Metabolic and Dietary Control in NIDDM , 1993, Diabetes Care.

[10]  R. Gregg,et al.  Abnormal in vivo metabolism of apolipoprotein E4 in humans. , 1986, The Journal of clinical investigation.

[11]  A. Avenell,et al.  Genetic variation and the lipid response to dietary intervention: a systematic review. , 2003, The American journal of clinical nutrition.

[12]  A. Lichtenstein,et al.  Effect of apolipoprotein E phenotype on diet-induced lowering of plasma low density lipoprotein cholesterol. , 1994, Journal of lipid research.

[13]  I. Makino,et al.  Increased frequencies of apolipoprotein ε2 and ε4 alleles in patients with ischemic heart disease , 1989 .

[14]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[15]  H. Gylling,et al.  SERUM CHOLESTEROL RESPONSE TO DIETARY CHOLESTEROL AND APOPROTEIN E PHENOTYPE , 1988, The Lancet.

[16]  K. Watanabe,et al.  Apolipoprotein E polymorphism and hyperlipoproteinemia in obesity. , 1989, International journal of obesity.

[17]  M. Laakso,et al.  Relation of coronary heart disease and apolipoprotein E phenotype in patients with non-insulin dependent diabetes. , 1991, BMJ.

[18]  D. T. Vernier,et al.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.

[19]  T. Lyons,et al.  Glycation and oxidation: a role in the pathogenesis of atherosclerosis. , 1993, The American journal of cardiology.

[20]  M. Eto,et al.  Increased Frequency of Apolipoprotein ∈4 Allele in Type II Diabetes With Hypercholesterolemia , 1987, Diabetes.

[21]  A. W. Pinrton.  The Invisible Worm , 1976, The Lancet.

[22]  D. Gordon,et al.  ApoE genotype does not predict lipid response to changes in dietary saturated fatty acids in a heterogeneous normolipidemic population. The DELTA Research Group. Dietary Effects on Lipoproteins and Thrombogenic Activity. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[23]  C. Ehnholm,et al.  Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. , 1987, The Journal of clinical investigation.

[24]  M. Katan,et al.  Characteristics of human hypo- and hyperresponders to dietary cholesterol. , 1987, American journal of epidemiology.

[25]  S. Rinzler,et al.  Primary prevention of coronary heart disease by diet. , 1967, American heart journal.

[26]  I. Makino,et al.  Apolipoprotein E allele frequencies in non-insulin-dependent diabetes mellitus with hypertriglyceridemia (type IIb, III, IV, and V hyperlipoproteinemia). , 1991, Metabolism: clinical and experimental.

[27]  A. Keys.  Serum cholesterol response to dietary cholesterol. , 1984, The American journal of clinical nutrition.